Marc Belsky Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Marc Belsky.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Marc Belsky. Marc Belsky is VP Finance and CAO in CELL GENESYS INC ($CEGE) and Senior Vice President and CFO in FIVE PRIME THERAPEUTICS INC ($FPRX) and SVP and CFO in FIVE PRIME THERAPEUTICS INC ($FPRX) and CFO in Kezar Life Sciences, Inc. ($KZR) and Chief Financial Officer in Kezar Life Sciences, Inc. ($KZR).
Latest Insider Trading Transactions of Marc Belsky
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, CEGE, FPRX, KZR
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 11 2021 | KZR | Kezar Life Science ... | Belsky Marc | CFO | Option Exercise | A | 5.45 | 220,000 | 1,199,000 | 220,000 | |
| Feb 05 2020 | KZR | Kezar Life Science ... | Belsky Marc | CFO | Buy | P | 2.60 | 15,384 | 39,998 | 15,384 | 0 to 15.4 K |
| Jan 13 2020 | KZR | Kezar Life Science ... | Belsky Marc | CFO | Option Exercise | A | 3.29 | 90,000 | 296,100 | 90,000 | |
| Jan 13 2020 | KZR | Kezar Life Science ... | Belsky Marc | CFO | Option Exercise | A | 3.29 | 90,000 | 296,100 | 90,000 | |
| Nov 13 2019 | KZR | Kezar Life Science ... | Belsky Marc | CFO | Buy | P | 2.76 | 800 | 2,207 | 2,000 | 1.2 K to 2 K (+66.67 %) |
| Nov 13 2019 | KZR | Kezar Life Science ... | Belsky Marc | CFO | Buy | P | 2.76 | 800 | 2,207 | 2,000 | 1.2 K to 2 K (+66.67 %) |
| Sep 10 2019 | KZR | Kezar Life Science ... | Belsky Marc | Chief Financial Off ... | Option Exercise | A | 3.38 | 60,000 | 202,800 | 60,000 | |
| Aug 12 2019 | KZR | Kezar Life Science ... | Belsky Marc | CFO | Buy | P | 4.82 | 500 | 2,410 | 1,000 | 500 to 1,000 (+100.00 %) |
| Jul 26 2019 | KZR | Kezar Life Science ... | Belsky Marc | CFO | Buy | P | 5.80 | 56 | 325 | 500 | 444 to 500 (+12.61 %) |
| Jul 26 2019 | KZR | Kezar Life Science ... | Belsky Marc | CFO | Buy | P | 5.65 | 444 | 2,510 | 444 | 0 to 444 |
| Jan 08 2019 | KZR | Kezar Life Science ... | Belsky Marc | Chief Financial Off ... | Option Exercise | A | 22.85 | 60,000 | 1,371,000 | 60,000 | |
| Feb 28 2018 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | Senior Vice Preside ... | Option Exercise | A | 18.69 | 18,000 | 336,420 | 18,000 | |
| Feb 28 2018 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | Senior Vice Preside ... | Grant | A | 0.00 | 3,000 | 0 | 16,314 | 13.3 K to 16.3 K (+22.53 %) |
| Feb 07 2018 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | Senior Vice Preside ... | Payment of Exercise | F | 18.42 | 1,048 | 19,304 | 13,314 | 14.4 K to 13.3 K (-7.30 %) |
| Sep 06 2017 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | Senior Vice Preside ... | Payment of Exercise | F | 34.34 | 921 | 31,627 | 16,982 | 17.9 K to 17 K (-5.14 %) |
| Mar 03 2017 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | Senior Vice Preside ... | Payment of Exercise | F | 44.77 | 18,881 | 845,302 | 46,785 | 65.7 K to 46.8 K (-28.75 %) |
| Feb 09 2017 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | Senior Vice Preside ... | Option Exercise | A | 45.38 | 22,500 | 1,021,050 | 22,500 | |
| Feb 09 2017 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | Senior Vice Preside ... | Grant | A | 0.00 | 7,031 | 0 | 12,656 | 5.6 K to 12.7 K (+125.00 %) |
| Feb 09 2017 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | Senior Vice Preside ... | Grant | A | 0.00 | 5,625 | 0 | 5,625 | 0 to 5.6 K |
| Jan 05 2017 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | Senior Vice Preside ... | Payment of Exercise | F | 48.60 | 2,281 | 110,857 | 65,666 | 67.9 K to 65.7 K (-3.36 %) |
| Sep 01 2016 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | Senior Vice Preside ... | Payment of Exercise | F | 44.74 | 17,980 | 804,425 | 67,947 | 50 K to 67.9 K (+35.98 %) |
| Aug 29 2016 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | Senior Vice Preside ... | Option Exercise | A | 43.71 | 30,000 | 1,311,300 | 30,000 | |
| Aug 29 2016 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | Senior Vice Preside ... | Grant | A | 0.00 | 5,000 | 0 | 85,927 | 80.9 K to 85.9 K (+6.18 %) |
| Apr 26 2016 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | Senior Vice Preside ... | Option Exercise | M | 19.25 | 3,052 | 58,751 | 41,948 | |
| Apr 26 2016 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | Senior Vice Preside ... | Option Exercise | M | 11.14 | 12,389 | 138,013 | 17,611 | |
| Apr 26 2016 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | Senior Vice Preside ... | Option Exercise | M | 7.26 | 11,178 | 81,152 | 5,082 | |
| Apr 26 2016 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | Senior Vice Preside ... | Option Exercise | M | 5.54 | 7,483 | 41,456 | 509 | |
| Apr 26 2016 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | Senior Vice Preside ... | Sell | S | 50.03 | 33,002 | 1,651,090 | 80,927 | 113.9 K to 80.9 K (-28.97 %) |
| Apr 26 2016 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | Senior Vice Preside ... | Sell | S | 49.24 | 1,100 | 54,164 | 113,929 | 115 K to 113.9 K (-0.96 %) |
| Apr 26 2016 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | Senior Vice Preside ... | Buy | M | 19.25 | 3,052 | 58,751 | 115,029 | 112 K to 115 K (+2.73 %) |
| Apr 26 2016 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | Senior Vice Preside ... | Buy | M | 11.14 | 12,389 | 138,013 | 111,977 | 99.6 K to 112 K (+12.44 %) |
| Apr 26 2016 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | Senior Vice Preside ... | Buy | M | 7.26 | 11,178 | 81,152 | 99,588 | 88.4 K to 99.6 K (+12.64 %) |
| Apr 26 2016 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | Senior Vice Preside ... | Buy | M | 5.54 | 7,483 | 41,456 | 88,410 | 80.9 K to 88.4 K (+9.25 %) |
| Mar 31 2016 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | Senior Vice Preside ... | Option Exercise | M | 4.56 | 9,052 | 41,277 | 351 | |
| Mar 31 2016 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | Senior Vice Preside ... | Option Exercise | M | 4.56 | 4,824 | 21,997 | 9,403 | |
| Mar 31 2016 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | Senior Vice Preside ... | Sell | S | 40.01 | 9,052 | 362,171 | 80,927 | 90 K to 80.9 K (-10.06 %) |
| Mar 31 2016 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | Senior Vice Preside ... | Buy | M | 4.56 | 9,052 | 41,277 | 89,979 | 80.9 K to 90 K (+11.19 %) |
| Mar 31 2016 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | Senior Vice Preside ... | Sell | S | 40.00 | 4,824 | 192,960 | 80,927 | 85.8 K to 80.9 K (-5.63 %) |
| Mar 31 2016 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | Senior Vice Preside ... | Buy | M | 4.56 | 4,824 | 21,997 | 85,751 | 80.9 K to 85.8 K (+5.96 %) |
| Apr 08 2016 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | Senior Vice Preside ... | Option Exercise | M | 5.54 | 138 | 765 | 7,992 | |
| Apr 08 2016 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | Senior Vice Preside ... | Option Exercise | M | 8.49 | 8,943 | 75,926 | 0 | |
| Apr 08 2016 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | Senior Vice Preside ... | Option Exercise | M | 6.89 | 11,382 | 78,422 | 0 | |
| Apr 08 2016 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | Senior Vice Preside ... | Option Exercise | M | 4.56 | 351 | 1,601 | 0 | |
| Apr 08 2016 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | Senior Vice Preside ... | Sell | S | 45.04 | 20,814 | 937,463 | 80,927 | 101.7 K to 80.9 K (-20.46 %) |
| Apr 08 2016 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | Senior Vice Preside ... | Buy | M | 5.54 | 138 | 765 | 101,741 | 101.6 K to 101.7 K (+0.14 %) |
| Apr 08 2016 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | Senior Vice Preside ... | Buy | M | 8.49 | 8,943 | 75,926 | 101,603 | 92.7 K to 101.6 K (+9.65 %) |
| Apr 08 2016 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | Senior Vice Preside ... | Buy | M | 6.89 | 11,382 | 78,422 | 92,660 | 81.3 K to 92.7 K (+14.00 %) |
| Apr 08 2016 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | Senior Vice Preside ... | Buy | M | 4.56 | 351 | 1,601 | 81,278 | 80.9 K to 81.3 K (+0.43 %) |
| Aug 21 2015 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | SVP and CFO | Grant | A | 0.00 | 75,000 | 0 | 80,680 | 5.7 K to 80.7 K (+1,320.42 %) |
| Aug 19 2015 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | SVP and CFO | Option Exercise | A | 19.25 | 45,000 | 866,250 | 45,000 | |
| May 04 2015 | FPRX | FIVE PRIME THERAPE ... | Belsky Marc | SVP and CFO | Grant | A | 0.00 | 5,680 | 0 | 5,680 | 0 to 5.7 K |
| Aug 01 2008 | CEGE | CELL GENESYS INC | Belsky Marc | VP Finance and CAO | Payment of Exercise | F | 3.11 | 3,664 | 11,377 | 6,456 | 10.1 K to 6.5 K (-36.21 %) |
| Feb 08 2008 | CEGE | CELL GENESYS INC | Belsky Marc | VP Finance and CAO | Option Exercise | A | 1.84 | 55,000 | 101,200 | 55,000 | |
| Aug 01 2007 | CEGE | CELL GENESYS INC | Belsky Marc | VP Finance and CAO | Grant | A | 0.00 | 10,120 | 0 | 10,120 | 0 to 10.1 K |
| Dec 05 2006 | CEGE | CELL GENESYS INC | Belsky Marc | VP Finance and CAO | Option Exercise | A | 3.80 | 50,000 | 190,000 | 50,000 |
Page: 1